Are peroxisome proliferator-activated receptors new therapeutic targets in diabetic and non-diabetic nephropathies?

Nephrology Dialysis Transplantation

Volumn 21, Issue 10, 2006, Pages 2696-2702

  Boulanger, Henri ^a   Mansouri, Rafik ^a   Gautier, Jean François ^a   Glotz, Denis ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Diabetic and non diabetic nephropathies; Peroxisome proliferator activated receptors (PPAR) , and agonists; Renal protection

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMILORIDE; ANTIDIABETIC AGENT; CISPLATIN; CYTOCHROME P450; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GLIBENCLAMIDE; GLICLAZIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIGAND; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; STREPTOZOCIN; SULFONYLUREA; TROGLITAZONE;

ACUTE KIDNEY FAILURE; ANTIINFLAMMATORY ACTIVITY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE MODEL; DRUG MECHANISM; DRUG TARGETING; FATTY ACID OXIDATION; FLUID RETENTION; GLOMERULOSCLEROSIS; HUMAN; IN VITRO STUDY; KIDNEY DISEASE; KIDNEY INJURY; KIDNEY ISCHEMIA; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; KIDNEY TUBULE FUNCTION; LIPID METABOLISM; LIPID STORAGE; MESANGIUM CELL; NATRIURESIS; NONHUMAN; NOTE; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; REPERFUSION INJURY;

ANIMALS; BLOOD PRESSURE; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY DISEASES; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; THIAZOLIDINEDIONES;

EID: 33749618160     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl448     Document Type: Note

References (53)

1. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1098; 98: 2088-2093
2. Guan Y, Zhang Y, Davis L, Breyer MD. Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans. Am J Physiol 1997; 273: F1013-F1022
3. Kamijo Y, Hora K, Tanaka N et al. Identification of functions of peroxisome proliferator-activated receptor alpha in proximal tubules. J Am Soc Nephrol 2002; 13: 1691-1702
4. db/db mice with type 2 diabetes. Diabetes 2005; 54: 2328-2335
5. Sun L, Halaihel N, Zhang W, Rogers T, Levi-M. Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomeruloselerosis in diabetes mellitus. J Biol Chem 2002; 277: 18919-18927
6. Jiang T, Liebman SE, Lucia MS, Phillips CL, Levi M. Calorie restriction modulates renal expression of sterol regulatory element-binding proteins, lipid accumulation, and age-related renal disease. J Am Soc Nephrol 2005; 16: 2385-2394
7. Jiang T, Wang Z, Protor G et al. Diet-induced obesity in C57BL/6J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway. J Biol Chem 2005; 280: 32317-32325
8. Nagothu KK, Bhatt R, Kaushal GP, Portilla D. Fibrate prevents cisplatin-induced proximal tubule cell death. Kidney Int 2005; 68: 268-2693
9. Portilla D, Dai G, Peters JM, Gonzales FJ, Crew MD, Proia AD. Etomoxir-induced PPARα-modulated enzymes protect during acute renal failure. Am J Physiol Renal Physiol 2000; 279: 675
10. Portilla D, Dai G, McClure T et al. PPARα ligand protects during cisplatin-induced acute renal failure by preventing inhibition of renal FAO and PDC activity. Am J Physiol Renal Physiol 2004; 286: F572-F580
11. Li S, Gokden N, Okusa MD, Bhatt R, Portilla D. Anti-inflammatory effect of fibrate protects from cisplatin-induced ARF. Am J Physiol Renal Physiol 2005; 289: F469-F480
12. Saga D, Sakatsume M, Ogawa A et al. Bezafibrate suppresses rat antiglomerular basement membrane crescentic glomerulonephritis. Kidney Int 2005; 67: 1821-1829
13. Ishizuka T, Ito O, Tan L et al. Regulation of cytochrome P-450 4A activity by peroxisome proliferator-activated receptors in the rat kidney. Hypertens Res 2003; 26: 929-936
14. Ma Y-H, Gebremedhin D, Chwartzman ML et al. 20-Hydroxyeicosatetraenoic acid is an endogenous vasoconstrictor of canine renal arcuate arteries. Circ Res 1993; 72: 126-136
15. Quingley R, Baum M, Reddy KM, Griener JC, Falck JR. Effects of 20-HETE and 19(S)-HETE on rabbit proximal straight tubule volume transport. Am J Physiol Renal Physiol 2000; 278: 949-953
16. Escalante B, Erlij D, Falck JR, Mc Giff JC. Effect of cytochrome P450 arachidonate metabolites on ion transport in rabbit kidney loop of Henle. Science 1991; 251: 799-802
17. Roman RJ, Ma YH, Frolich B, Merkham B. Clofibrate prevents the development of hypertension in Dahl salt-sensitive rats. Hypertension 1993; 21: 985-988
18. Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Result from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2005; 45: 485-493
19. The FIELD study investigators. Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 2005; 366: 1849-1861
20. Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: A double-blind, randomized trial. J Clin Endocrinol Metab 2004; 89: 6068-6076
21. Hong G, Lockhart A, Davis B et al. PPAR gamma activation enhances cell surface ENaC alpha via up-regulation of SGK1 in human collecting duct cells. FASEB J 2003; 17: 1966-1968
22. Guan Y, Hao C, Cha DR et al. Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption. Nat Med 2005; 11: 861-866
23. Kalambokis GN, Tsatsoulis AA, Tsianos EV. The edematogenic properties of insulin. Am J Kidney Dis 2004; 44: 575-590
24. Mudaliar S, Chang AR, Henry RR. Thiazolidinediones, peripheral edema, and type 2 diabetes: Incidence, pathophysiology and clinical implications. Endocr Pract 2003; 9: 406-416
25. Calnek DS, Mazzella L, Roser S, Roman J, Hart MC. Peroxisome proliferator-activated receptor γ ligands increase release of nitric oxide from endothelial cells. Aterioscler Thromb Vasc Biol 2003; 23: 52-57
26. Zhang F, Sowers JR, Ram JL, Standley PR, Peuler JD. Effects of pioglitazone on calcium channels in vascular smooth muscle. Hypertension 1994; 24: 170-175
27. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109: 2054-2057
28. Asano T, Wakisaka M, Yoshinari M et al. Peroxisome proliferator-activated receptor γ1 (PPARγ1) expresses in rat mesangial cells and PPARγ agonists modulate its differentiation. Biochim Biophys Acta 2000; 1497: 178-184
29. Tsuchiya T, Shimizu H, Shimomura K, Mori M. Troglitazone inhibits isolated cell proliferation, and induces apoptosis in isolated rat mesangial cells. Am J Nephrol 2003; 23: 222-228
30. Ghosh SS, Gehr TW, Ghosb S et al. PPARγ ligand attenuates PDGF-induced mesangial cell proliferation: Role of MAP kinase. Kidney Int 2003; 64: 52-62
31. Routh RE, Johnson JH, McCarthy KJ. Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro. Kidney Int 2002; 61: 1365-1376
32. Li Y, Wen X, Spataro BC et al. Hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-γ agonists. J Am Soc Nephrol 2006; 17: 54-65
33. Zafiriou S, Stanners SR, Polhill TS, Pollock CA. Pioglitazone increases renal tubular cell albumin uptake but limits pro-inflammatory and fibrotic responses. Kidney Int 2004; 65: 1647-1653
34. Panchapakesan U, Pollock CA, Chen XM. The effect of high glucose and PPAR-γ agonists on PPARγ expression and function in HK-2 cells. Am J Physiol Renal Physiol 2004; 287: F528-F534
35. Buckingham RE, Al-Barazanji KA, Toseland CD et al. Peroxisome proliferator-activated receptor-γ agonist, rosiglita-zone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 1998; 47: 1326-1334
36. Baylis C, Atzpodien EA, Freshour G, Engels K. Peroxisome proliferator-activated receptor γ agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity. J Pharmacol Exp Ther 2003; 307: 854-860
37. Isshiki K, Haneda M, Koya D, Maeda S, Sugimoto T, Kikkawa R. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes 2000; 49: 1022-1032
38. Sivarajah A, Chatterjee PK, Patel NS et al. Agonists of peroxisome-proliferator activated receptor-gamma reduce renal ischemia/ reperfusion injury. Am J Nephrol 2003; 23: 267-276
39. Chung BH, Li C, Sun BK et al. Rosiglitazone protects against cyclosporine-induced pancreatic and renal injury in rats. Am J Transplant 2005; 5: 1856-1867
40. Lee S, Kim W, Kang KP et al. Agonist of peroxisome proliferator-activated receptor-γ, rosiglitazone, reduces renal injury and dysfunction in a murine sepsis model. Nephrol Dial Transplant 2005; 20: 1057-1065
41. Ma LJ, Marcantoni C, Linton MF, Fazio S, Fogo AB. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against non diabetic glomerulosclerosis in rats. Kidney Int 2001; 59: 1899-1910
42. Lebovitz HE, Dole JF, Patwardhan R, Rappapport B, Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 280-288
43. Yanagawa T, Araki A, Sasamoto K, Shirabe S, Yamanouchi T. Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes. Metabolism 2004; 53: 353-357
44. Bakris G, Viberti G, Weston WM, Heise M, Porter LE, Freed MI. Rosiglitazone reduces urinary albumin excretion in type 2 diabetes. J Hum Hypertens 2003; 17: 7-12
45. Grossman E. Rosiglitazone reduces blood pressure and urinary albumin excretion in type 2 diabetes: G Bakris et al. J Hum Hypertens 2003; 17: 5-6
46. Nakaruma T, Ushiyama C, Suzuki S et al. Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in type 2 diabetic patients with microalbuminuria or macroalbuminuria. Diabet Med 2001; 18: 308-313
47. Imano E, Kanda T, Nakatani Y et al. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 1998; 21: 2135-2139
48. Shernthaner G, Matthews DF, Charbonnel B, Hanefeld M, Brunetti P. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: A doubleblind, randomized trial. J Clin Endocrinol Metab 2004; 89: 6068-6076
49. Dormandy JA, Charbonnel B, Eckland DJA et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289
50. Herrmann SM, Ringel J, Wang JG, Staessen JA, Brand E. Peroxisome proliferator-activated receptor-γ2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes. Diabetes 2002; 51: 2653-2657
51. Guan Y, Breyer MD. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int 2001; 60: 14-30
52. Escher P, Braissant O, Basu-Mondak S, Michalik L, Wahli W, Desvergne B. Rat PPARs: Quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 2001; 142: 4195-4202
53. Letavernier E. Perez J, Joye E et al. Peroxisome proliferator-activated receptorβ/δ exerts a strong protection from ischemi acute renal failure. J Am Soc Nephrol 2005; 16: 2395-2402